The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers that publishes free evidence-based, ...
New NSCLC guideline updates outline expanded perioperative immunotherapy, adjuvant targeted therapy, and consolidation strategies, supported by phase III data and informed by molecular testing.
About KOMZIFTI™ KOMZIFTI (ziftomenib) is an oral menin inhibitor approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation ...
Crystal Denlinger, MD, FACP, incoming CEO of the National Comprehensive Cancer Network (NCCN), talks about the organization’s challenges and solutions to keeping up with the ever-changing oncology ...
During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...
MedPage Today on MSN
Managing Relapsed/Refractory Multiple Myeloma in Rural America
Unique challenges that have some solutions, but more are needed ...
Amgen (AMGN) just received full approval from the FDA for IMDELLTRA in treating adult patients with extensive stage small ...
The National Comprehensive Cancer Network Oncology Research Program announces funding for researchers from Indiana University Melvin and Bren Simon Comprehensive Cancer Center, UC Davis Comprehensive ...
The National Comprehensive Cancer Network joins a global day of advocacy to put people's individual needs and stories at the forefront of cancer care. World Cancer Day 2025 marks the start of the ...
Free information from the National Comprehensive Cancer Network offers information on how and why to access genetic counseling and testing for multiple hereditary cancers “No other landscape in ...
On Friday, March 13, 2015, as part of its 20th Annual Conference: Advancing the Standard of Cancer Care™, the National Comprehensive Cancer Network® (NCCN®) hosted its second roundtable, Value-Based ...
The National Comprehensive Cancer Network ® (NCCN ®) - an alliance of leading cancer centers - today published its first ever set of treatment recommendations pertaining to neuroblastoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results